Ranbaxy Announces U.S. FDA Approval Of CIP-Isotretinoin NDA
Product to be launched as Absorica™ In the U.S. Market in Q4 2012
Princeton, N.J /PRNewswire/ — Ranbaxy Laboratories inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica™, a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne. Through a business agreement with the Canadian firm, Cipher Pharmaceuticals inc., RLI is expected to launch Absorica™ in the U.S. in Q4 2012. as per the agreement, Ranbaxy will pay royalties on net sales to Cipher.
"We are …
Read User's Comments0